Agenus (NASDAQ:AGEN) Stock Price Crosses Above Two Hundred Day Moving Average of $2.31

Agenus Inc. (NASDAQ:AGENGet Rating) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.31 and traded as high as $2.36. Agenus shares last traded at $2.29, with a volume of 1,931,379 shares trading hands.

Analysts Set New Price Targets

Separately, TheStreet downgraded shares of Agenus from a “c-” rating to a “d” rating in a research report on Friday, May 27th.

Agenus Trading Down 0.9 %

The stock has a market capitalization of $648.44 million, a PE ratio of 22.90 and a beta of 1.17. The stock’s fifty day simple moving average is $2.69 and its 200-day simple moving average is $2.31.

Agenus (NASDAQ:AGENGet Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. Agenus had a net margin of 3.07% and a return on equity of 11.65%. During the same quarter in the prior year, the business posted ($0.37) EPS. As a group, analysts anticipate that Agenus Inc. will post -0.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

A number of hedge funds and other institutional investors have recently made changes to their positions in AGEN. Captrust Financial Advisors raised its stake in Agenus by 12.0% in the 2nd quarter. Captrust Financial Advisors now owns 613,692 shares of the biotechnology company’s stock valued at $1,191,000 after acquiring an additional 65,846 shares during the period. Legal & General Group Plc raised its stake in Agenus by 16.3% in the 2nd quarter. Legal & General Group Plc now owns 123,189 shares of the biotechnology company’s stock valued at $239,000 after acquiring an additional 17,293 shares during the period. Goldman Sachs Group Inc. raised its stake in Agenus by 59.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 2,434,396 shares of the biotechnology company’s stock valued at $4,723,000 after acquiring an additional 911,006 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Agenus by 21.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 163,074 shares of the biotechnology company’s stock valued at $316,000 after acquiring an additional 29,045 shares during the period. Finally, AQR Capital Management LLC raised its stake in Agenus by 122.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,156,812 shares of the biotechnology company’s stock valued at $2,244,000 after acquiring an additional 635,794 shares during the period. 51.89% of the stock is owned by hedge funds and other institutional investors.

About Agenus

(Get Rating)

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Read More

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.